Virginia Bottomley - Smith Nephew Non-Executive Independent Director

SNNUF Stock  USD 12.71  0.15  1.17%   

Director

Rt. Hon. Baroness Virginia Hilda Brunette Maxwell Bottomley is NonExecutive Independent Director of Smith Nephew PLC., since April 12, 2012. She is a Member of the Remuneration Committee and Nomination Governance Committee in April 2014 and will join the Compliance Culture Committee in April 2019. Career and experience Virginia gained her MSc in Social Administration from the London School of Economics following her first degree. She was appointed a Life Peer in 2005 following her career as a Member of Parliament between 1984 and 2005. She served successively as Secretary of State for Health and then Culture, Media and Sport. Virginia was formerly a Director of Bupa and AkzoNobel NV. She is currently a Director of International Resources Group Limited, where she is Chair of Board CEO Practice at Odgers Berndtson. She is a member of the International Advisory Council of Chugai Pharmaceutical Co., Chancellor of University of Hull and Sheriff of Kingston upon Hull. She is a Trustee of The Economist Newspaper. Skills and competencies Virginias extensive experience within Government, particularly as Secretary of State for Health, brings a unique insight into the healthcare system both in the UK and globally, whilst her experience on the board of Bupa brings an understanding of the private healthcare sector and an insight into the needs of our customers. Her experience running the board practice at a search firm gives her a valuable skillset as a member of the Nomination Governance Committee and Remuneration Committee. Her long association with Hull, the home of many of our UK employees, also brings an added perspective. since 2012.
Age 70
Tenure 12 years
Phone44 1923 477 100
Webhttps://www.smith-nephew.com

Smith Nephew Management Efficiency

The company has return on total asset (ROA) of 0.0425 % which means that it generated a profit of $0.0425 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.0925 %, meaning that it generated $0.0925 on every $100 dollars invested by stockholders. Smith Nephew's management efficiency ratios could be used to measure how well Smith Nephew manages its routine affairs as well as how well it operates its assets and liabilities.
The company has accumulated 2.71 B in total debt with debt to equity ratio (D/E) of 0.54, which is about average as compared to similar companies. Smith Nephew Plc has a current ratio of 1.74, which is within standard range for the sector. Debt can assist Smith Nephew until it has trouble settling it off, either with new capital or with free cash flow. So, Smith Nephew's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Smith Nephew Plc sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Smith to invest in growth at high rates of return. When we think about Smith Nephew's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

DIRECTOR Age

Jay SkylerDexCom Inc
71
Shirley JacksonMedtronic PLC
70
Robert PozenMedtronic PLC
71
Elizabeth NabelMedtronic PLC
69
Maria HiladoZimmer Biomet Holdings
56
Ronda StrykerStryker
66
Patricia GonzalezAbbott Laboratories
49
Yoshiaki FujimoriBoston Scientific Corp
69
Nicholas AugustinosDexCom Inc
59
Michael FarrellZimmer Biomet Holdings
48
Jeffrey RhodesZimmer Biomet Holdings
41
Louise FrancesconiStryker
66
Susan SiegelAlign Technology
57
Anne MyongAlign Technology
51
Stephen MacMillanBoston Scientific Corp
56
Zachary CPAZimmer Biomet Holdings
N/A
Eric TopolDexCom Inc
63
Richard CollinsDexCom Inc
61
Glenn TiltonAbbott Laboratories
72
Mark FolettaDexCom Inc
57
Roch DoliveuxStryker
64
Smith Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices worldwide. Smith Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom. Smith Nephew operates under Medical Devices classification in the United States and is traded on OTC Exchange. It employs 18000 people. Smith Nephew Plc [SNNUF] is a Pink Sheet which is traded between brokers as part of OTC trading.

Management Performance

Smith Nephew Plc Leadership Team

Elected by the shareholders, the Smith Nephew's board of directors comprises two types of representatives: Smith Nephew inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Smith. The board's role is to monitor Smith Nephew's management team and ensure that shareholders' interests are well served. Smith Nephew's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Smith Nephew's outside directors are responsible for providing unbiased perspectives on the board's policies.
Namal Nawana, CEO, Executive Director
Michael Friedman, Non-Executive Independent Director
Diogo MoreiraRato, President - Europe and Canada
Alison Parkes, Chief Officer
Skip Kiil, President - Orthopedics
Erik Engstrom, Non-Executive Director
Deepak Nath, CEO Director
Matthew Stober, President - Global Operations
Marc Owen, Non-Executive Director
AnneFrancoise Nesmes, CFO Director
Helen Barraclough, Company Counsel
Rodrigo Bianchi, President IRAMEA
Brian Larcombe, Senior Independent Non-Executive Director
Elga Lohler, Chief Human Resource Officer
Bradley Cannon, Sports Orthopaedics
Gunthorp Oie, IR Contact Officer
Roland Diggelmann, Non-Executive Director
Helen Maye, Chief Human Resources Officer
Vinita Bali, Non-Executive Director
Simon Fraser, President - Advanced Wound Management
Massimiliano Colella, President Europe - Middle East and Africa
Olivier Bohuon, CEO, Director, Chairman of Disclosures Committee, Chairman of Executive Risk Committee and Member of Nomination and Governance Committee
Graham Baker, CFO, Executive Director
Cathy ORourke, Chief Legal and Compliance Officer
Roberto Quarta, Non-Executive Independent Chairman of the Board
Joe Metzger, VP Communications
Cyrille Petit, Chief Corporate Development Officer
Julie Brown, CFO, Director and Member of Disclosures Committee
Glenn Warner, President - Advanced Wound Management
Robin Freestone, Non-Executive Director
Paul Connolly, Pres Operations
Virginia Bottomley, Non-Executive Independent Director
Phil Cowdy, Executive Vice President of Business Development & Corporate Affairs
Angie Risley, Non-Executive Director
Mark Gladwell, President - Global Operations
Andrew Swift, VP Relations
Vasant Padmanabhan, President - Research & Development
Michael Frazzette, President - Advanced Surgical Devices
Joseph Papa, Non-Executive Independent Director
Ingeborg Oie, VP, Investor Relations
Susan Swabey, Company Secretary
Melissa Guerdan, Chief Quality and Regulatory Affairs Officer
Philip Cowdy, Chief Officer
Gordon Howe, President of Global Operations
John Campo, Chief Legal Officer
Brad Cannon, President Europe and Canada
Ian Barlow, Non-Executive Independent Director
Catheryn ORourke, Chief Legal Officer

Smith Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Smith Nephew a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Currently Active Assets on Macroaxis

Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Smith Nephew Plc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in employment.
You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.

Complementary Tools for Smith Pink Sheet analysis

When running Smith Nephew's price analysis, check to measure Smith Nephew's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Smith Nephew is operating at the current time. Most of Smith Nephew's value examination focuses on studying past and present price action to predict the probability of Smith Nephew's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Smith Nephew's price. Additionally, you may evaluate how the addition of Smith Nephew to your portfolios can decrease your overall portfolio volatility.
Transaction History
View history of all your transactions and understand their impact on performance
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Sectors
List of equity sectors categorizing publicly traded companies based on their primary business activities
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Funds Screener
Find actively-traded funds from around the world traded on over 30 global exchanges
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
Please note, there is a significant difference between Smith Nephew's value and its price as these two are different measures arrived at by different means. Investors typically determine if Smith Nephew is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Smith Nephew's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.